3/26
08:14 am
pvla
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.
Low
Report
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.
3/26
06:22 am
pvla
Palvella Therapeutics (NASDAQ: PVLA) was upgraded by analysts at Jones Trading to a "strong-buy" rating.
Low
Report
Palvella Therapeutics (NASDAQ: PVLA) was upgraded by analysts at Jones Trading to a "strong-buy" rating.
3/25
08:40 am
pvla
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at Jones Trading. They set a "buy" rating and a $45.00 price target on the stock.
Low
Report
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at Jones Trading. They set a "buy" rating and a $45.00 price target on the stock.
3/18
08:30 am
pvla
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
Medium
Report
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
3/17
04:41 am
pvla
Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well [Yahoo! Finance]
Medium
Report
Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well [Yahoo! Finance]
3/10
08:37 am
pvla
Eli Lilly's three-year Ebglyss study leaves 50% of AD patients with clear skin [Yahoo! Finance]
Low
Report
Eli Lilly's three-year Ebglyss study leaves 50% of AD patients with clear skin [Yahoo! Finance]
3/7
08:40 am
pvla
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $50.00 price target on the stock.
Low
Report
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $50.00 price target on the stock.
2/26
12:49 pm
pvla
Palvella Therapeutics (NASDAQ: PVLA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $39.00 price target on the stock.
Neutral
Report
Palvella Therapeutics (NASDAQ: PVLA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $39.00 price target on the stock.
2/25
08:00 am
pvla
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
Medium
Report
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
2/20
07:13 am
pvla
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $39.00 price target on the stock.
High
Report
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $39.00 price target on the stock.
2/11
08:09 am
pvla
Palvella Therapeutics (NASDAQ: PVLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Medium
Report
Palvella Therapeutics (NASDAQ: PVLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
2/10
09:32 am
pvla
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old [Yahoo
Low
Report
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old [Yahoo
2/10
08:00 am
pvla
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Medium
Report
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
2/5
07:19 am
pvla
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at TD Cowen. They set a "buy" rating and a $44.00 price target on the stock.
Medium
Report
Palvella Therapeutics (NASDAQ: PVLA) is now covered by analysts at TD Cowen. They set a "buy" rating and a $44.00 price target on the stock.
1/10
08:15 am
pvla
Palvella Therapeutics (NASDAQ: PVLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Low
Report
Palvella Therapeutics (NASDAQ: PVLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
1/10
08:00 am
pvla
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
Low
Report
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
1/8
08:00 am
pvla
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
Low
Report
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
1/3
08:00 am
pvla
Palvella Therapeutics (NASDAQ: PVLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
High
Report
Palvella Therapeutics (NASDAQ: PVLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.